Pharmacokinetics of 111In- and 125I-labeled antiTac single-chain Fv recombinant immunotoxin

Journal of Nuclear Medicine

Volumn 41, Issue 4, 2000, Pages 755-762

  Kobayashi, Hisataka ^b   Kao, Chih Hao K ^b   Kreitman, Robert J ^b   Le, Nhat ^b   Kim, Meyoung Kon ^b   Brechbiel, Martin W ^b   Paik, Chang H ^b   Pastan, Ira ^b   Carrasquillo, Jorge A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NONE

Author keywords

111ln; 125I; Immunotoxin; Interleukin 2 receptor subunit; Monoclonal antibody

Indexed keywords

IMMUNOTOXIN; INDIUM 111; IODINE 125; MONOCLONAL ANTIBODY; ANTIBODY; ANTITAC(FV) PE38 RECOMBINANT IMMUNOTOXIN; ANTITAC(FV)-PE38 RECOMBINANT IMMUNOTOXIN; DIAGNOSTIC AGENT; INDIUM; INTERLEUKIN 2 RECEPTOR; RADIOACTIVE IODINE; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CYTOTOXICITY; DRUG DISTRIBUTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTERNALIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; IMMUNOLOGY; NUDE MOUSE; TISSUE DISTRIBUTION;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; IMMUNOTOXINS; INDIUM RADIOISOTOPES; IODINE RADIOISOTOPES; MICE; MICE, NUDE; RECEPTORS, INTERLEUKIN-2; RECOMBINANT PROTEINS; TISSUE DISTRIBUTION;

EID: 0033625126     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Hwang J, Fitzgerald DJ, Adhya S, Pastan I. Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell. 1987;48:129-136.
2. Chaudhary VK, Queen C, Junghans RP, Waldmann TA, FitzGerald DJ, Pastan I. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature. 1989;339:394-397.
3. Kreitman RJ, Chang CN, Hudson DV, Queen C, Bailon P, Pastan I. Anti-Tac(Fab)-PE40, a recombinant double-chain immunotoxin which kills interleukin-2-receptor-bearing cells and induces complete remission in an in vivo tumor model. Int J Cancer. 1994;57:856-864.
4. Kreitman RJ, Pastan I. Targeting Pseudomonas exotoxin to hematologic malignancies. Semin Cancer Biol. 1995;6:297-306.
5. Murphy JR, vanderSpek JC. Targeting diphtheria toxin to growth factor receptors. Semin Cancer Biol. 1995;6:259-267.
6. Amlot PL, Stone MJ, Cunningham D, et al. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood. 1993;82:2624-2633.
7. Vitetta ES, Stone M, Amlot P, et al. Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res. 1991;51:4052-4058.
8. Sausville EA, Headlee D, Stetler-Stevenson M, et al. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study. Blood. 1995;85:3457-3465.
9. Engert A, Diehl V, Schnell R, et al. A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood. 1997;89:403-410.
10. Stone MJ, Sausville EA, Fay JW, et al. A phase I study of bolus versus continuous infusion of the anti-CD 19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood. 1996;88:1188-1197.
11. Uckun FM. Immunotoxins for the treatment of leukaemia. Br J Haematol. 1993;85:435-438.
12. Grossbard ML, Lambert JM, Goldmacher VS, et al. Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J Clin Oncol. 1993;11:726-737.
13. Pai LH, Wittes R, Setser A, Willingham MC, Pastan I. Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nat Med. 1996;2:350-353.
14. LeMaistre CF, Saleh MN, Kuzel TM, et al. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood. 1998;91:399-405.
15. Kreitman RJ, Pastan I. Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responses. Cancer Res. 1998;58:968-975.
16. Mujoo K, Cheung L, Murray JL, Rosenblum MG. Pharmacokinetics, tissue distribution, and in vivo antitumor effects of the antimelanoma immunotoxin ZME-gelonin. Cancer Immunol Immunother. 1995;40:339-345.
17. Uchiyama T, Nelson DL, Fleisher TA, Waldmann TA. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells. J Immunol. 1981;126:1398-1403.
18. Kreitman RJ, Bailon P, Chaudhary VK, FitzGerald DJ, Pastan I. Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma. Blood. 1994;83:426-434.
19. Waldmann TA. IL-2 receptor expression in the haematologic malignancies: a target for immunotherapy. Cancer Surv. 1989;8:891-903.
20. 125I radiolabeled T101 anti-CD5 monoclonal antibody. Int J Rad Appl Instrum [B]. 1990;17:201-207.
21. Press OW, Shan D, Howell-Clark J, et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res. 1996;56:2123-2129.
22. van Oosterhout YV, Preijers FW, Wessels HM, de Witte T. Cytotoxicity of CD3-ricin A chain immunotoxins in relation to cellular uptake and degradation kinetics. Cancer Res. 1992;52:5921-5925.
23. Rosenblum MG, Cheung L, Kim SK, Mujoo K, Donato NJ, Murray JL. Cellular resistance to the antimelanoma immunotoxin ZME-gelonin and strategies to target resistant cells. Cancer Immunol Immunother. 1996;42:115-121.
24. 99mTc-labeled anti-Tac dsFv. Cancer Res. 1996;56:3788-3795.
25. Mirzadeh S, Brechbiel MW, Atcher RW, Gansow OA. Radiometal labeling of immunoproteins: covalent linkage of 2-(4-isothiocyanatobenzyl) diethylenetri-aminepentaacetic acid ligands to immunoglobulin. Bioconjug Chem. 1990;1:59-65.
26. Kobayashi H, Wu C, Yoo TM, et al. Evaluation of the in vivo biodistribution of yttrium-labeled isomers of CHX-DTPA-conjugated monoclonal antibodies. J Nucl Med. 1998;39:829-836.
27. Wu C, Kobayashi H, Sun B, et al. Stereochemical influence on the stability of radio-metal complexes in vivo: synthesis and evaluation of the four stereoisomers of 2-(p-nitrobenzyl)-trans-CyDTPA. Bioorg Med Chem. 1997;5:1925-1934.
28. Wu C, Brechbiel MW, Kozak RW, Gansow OA. Metal-chelate-dendrimer-antibody constructs for use in radioimmunotherapy and imaging. Bioorg Med Chem Lett. 1994;4:449-454.
29. Camera L, Kinuya S, Garmestani K, et al. Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA). Eur J Nucl Med. 1994;21: 640-646.
30. Camera L, Kinuya S, Garmestani K, et al. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. J Nucl Med. 1994;35:882-889.
31. Chiron MF, Fryling CM, FitzGerald DJ. Cleavage of Pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver. J Biol Chem. 1994;269:18167-18176.
32. Ogata M, Fryling CM, Pastan I, FitzGerald DJ. Cell-mediated cleavage of Pseudomonas exotoxin between Arg279 and Gly280 generates the enzymatically active fragment which translocates to the cytosol. J Biol Chem. 1992;267:25396-25401.
33. Chiron MF, Fryling CM, FitzGerald D. Furin-mediated cleavage of Pseudomonas exotoxin-derived chimeric toxins. J Biol Chem. 1997;272:31707-31711.
34. 125I-labeled anti-Tac disulfide-stabilized Fv fragment by blocking its binding to the α subunit of interleukin-2 receptor in the circulation with preinjected humanized anti-Tac IgG. Cancer Res. 1997;57:1955-1961.
35. 212Bi-anti-Tac. Cancer Res 1994;54:4362-4370.
36. Kreitman RJ, Pastan I. Recombinant single-chain immunotoxins against T and B cell leukemias. Leuk Lymphoma. 1994;13:1-10.
37. Kobayashi H, Sakahara H, Hosono M, et al. Improved clearance of radiolabeled biotinylated monoclonal antibody following the infusion of avidin as a chase without decreased accumulation in the target tumor. J Nucl Med. 1994;35:1677-1684.
38. Schott ME, Schlom J, Siler K, et al. Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide-labeled immunoconjugates. Cancer. 1994; 73:993-998.
39. Carrasquillo JA, Mulshine JL, Bunn PAJ, et al. Indium-111 T101 monoclonal antibody is superior to iodine-131 T101 in imaging of cutaneous T-cell lymphoma. J Nucl Med. 1987;28:281-287.
40. Kreitman RJ, Wilson W, Waldmann TA, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies [abstract]. Blood. 1998;92:413A.